Mahadevan Kumar1, M Mugunthan2, Rajan Kapoor3, Suresh Pandalanghat4. 1. Professor (Microbiology), Army Hospital (R&R), Delhi Cantt 110010, India. 2. Consultant (Microbiologist), Yashoda Hospital, Hyderabad, Telengana, India. 3. Senior Adviser (Haematology), Army Hospital (R&R), Delhi Cantt 110010, India. 4. Senior Adviser (Oncology), Command Hospital (Eastern Command), Kolkata, India.
Abstract
BACKGROUND: Invasive fungal diseases (IFDs) are difficult to diagnose and associated with high mortality rates, especially in the immunosuppressed. Species of Aspergillus and Candida are the cause of majority of invasive fungal disease however IFDs are also caused by Fusarium, Zygomycetes, Trichosporon, etc. Early detection is crucial for appropriate antifungal therapy. Blood cultures usually fail to isolate filamentous fungi, while detection of circulating beta-d-glucan or galactomannan antigens show variable sensitivity and specificity. There is a need of reliable, sensitive and specific diagnostic tests for IFDs. METHODS: A real-time Polymerase Chain Reaction (PCR) assay with a universal primer/molecular beacon system was developed for detecting and speciating most of the pathogenic fungi implicated in IFD. A single-reaction assay was designed targeting a carefully selected region of the ITS2 and ITS5 subunits of the fungal rDNA gene along with four molecular beacons capable of differential hybridization to the amplicons of different species. This generated a signature set of melting temperatures using the standard strains. The assay was tested on clinical specimens from patients with suspected invasive fungal disease. RESULTS: The assay was tested on 72 clinical samples and 72 healthy controls. Of these, 22 clinical samples (6/8 proven; 13/29 probable; 3/35 possible IFD, classified by the EORTC/MSG criteria) were positive by PCR and generated a set of melting temperatures enabling identification of the causative fungus. The assay was negative in all healthy controls. CONCLUSION: The molecular beacon assay is a promising tool providing a rapid method for detection and monitoring of invasive fungal disease in immunosuppressed patients.
BACKGROUND: Invasive fungal diseases (IFDs) are difficult to diagnose and associated with high mortality rates, especially in the immunosuppressed. Species of Aspergillus and Candida are the cause of majority of invasive fungal disease however IFDs are also caused by Fusarium, Zygomycetes, Trichosporon, etc. Early detection is crucial for appropriate antifungal therapy. Blood cultures usually fail to isolate filamentous fungi, while detection of circulating beta-d-glucan or galactomannan antigens show variable sensitivity and specificity. There is a need of reliable, sensitive and specific diagnostic tests for IFDs. METHODS: A real-time Polymerase Chain Reaction (PCR) assay with a universal primer/molecular beacon system was developed for detecting and speciating most of the pathogenic fungi implicated in IFD. A single-reaction assay was designed targeting a carefully selected region of the ITS2 and ITS5 subunits of the fungal rDNA gene along with four molecular beacons capable of differential hybridization to the amplicons of different species. This generated a signature set of melting temperatures using the standard strains. The assay was tested on clinical specimens from patients with suspected invasive fungal disease. RESULTS: The assay was tested on 72 clinical samples and 72 healthy controls. Of these, 22 clinical samples (6/8 proven; 13/29 probable; 3/35 possible IFD, classified by the EORTC/MSG criteria) were positive by PCR and generated a set of melting temperatures enabling identification of the causative fungus. The assay was negative in all healthy controls. CONCLUSION: The molecular beacon assay is a promising tool providing a rapid method for detection and monitoring of invasive fungal disease in immunosuppressed patients.
Entities:
Keywords:
Invasive fungal disease; Molecular beacons; Real time PCR
Authors: N E Jordanides; E K Allan; L A McLintock; M Copland; M Devaney; K Stewart; A N Parker; P R E Johnson; T L Holyoake; B L Jones Journal: Bone Marrow Transplant Date: 2005-02 Impact factor: 5.483
Authors: S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh Journal: Clin Infect Dis Date: 2001-11-26 Impact factor: 9.079
Authors: Hadir A El-Mahallawy; Heba H Shaker; Hala Ali Helmy; Tarek Mostafa; Abdel Razak Abo-Sedah Journal: Med Mycol Date: 2006-12 Impact factor: 4.076
Authors: Shahid Husain; Barbara D Alexander; Patricia Munoz; Robin K Avery; Sally Houston; Timothy Pruett; Richard Jacobs; Edward A Dominguez; Jan G Tollemar; Katherine Baumgarten; Chen M Yu; Marilyn M Wagener; Peter Linden; Shimon Kusne; Nina Singh Journal: Clin Infect Dis Date: 2003-07-09 Impact factor: 9.079